Equibles does not estimate personal net worth.
Get an email with a short summary when Definium Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DFTX alertsThe proxy statement of Definium Therapeutics, Inc. reports total compensation of $4,001,258 for Daniel Karlin in fiscal 2025, including a base salary of $510,000. Disclosed compensation is on record for 4 fiscal years. Daniel Karlin has spoken on 1 earnings call across 1 company, most recently for Definium Therapeutics, Inc. on June 22, 2026. Definium Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Definium Therapeutics, Inc. includes Dr. Roger Crystal (CEO), Dr. Suzanne Bruhn (CEO), JR Rahn (CEO) and 7 others.
“I'll provide an update on the status of our clinical programs with a focus on where each of our late-stage studies stands today and how those studies were designed to assess what we believe would constitute a clinically meaningful outcome, starting with DT120-ODT.”
Proxy statement
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Definium Therapeutics, Inc. (DFTX) | Chief Medical Officer | $510,000 | $4,001,258 |
| 2024 | Definium Therapeutics, Inc. (DFTX) | Chief Medical Officer | $485,500 | $1,330,319 |
| 2023 | Definium Therapeutics, Inc. (DFTX) | Chief Medical Officer | $462,500 | $1,037,272 |
| 2021 | Definium Therapeutics, Inc. (DFTX) | Chief Medical Officer | $291,667 | $4,905,942 |
